<DOC>
	<DOCNO>NCT00435604</DOCNO>
	<brief_summary>This Phase I , randomize , double-blinded , within-subject control , two-way crossover study compare time inject ( flow rate ) , safety , tolerability subcutaneously ( SC ) administer , viscous antibody solution without human recombinant hyaluronidase ( rHuPH20 ) volunteer subject . The study hypothesizes time required complete 20-mL SC injection viscous antibody rHuPH20 comparable short time require injection without rHuPH20 .</brief_summary>
	<brief_title>A Study Subcutaneous Injection Viscous Antibody Solution With Recombinant Human Hyaluronidase</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Volunteers either sex , age 18 65 year , inclusive . 2 . Intact normal skin upper extremity without tattoo potentially obscure pigmentation lesion . 3 . Vital sign ( BP , HR , temperature , respiratory rate ) within normal range . 4 . Metabolic panel ( e.g. , sodium , potassium , chloride , bicarbonate , BUN , creatinine , glucose , calcium , AST , ALT , alkaline phosphatase , total bilirubin , albumin , total protein ) within normal range within 7 day injection . 5 . A negative serum urine pregnancy test ( female childbearing potential ) within 7 day injection . 6 . Female subject childbearing potential must practice effective birth control abstinence currently plan continue duration study . 7 . Decisionmaking capacity willingness ability comply requirement full completion trial . 8 . Willingness ability sign inform consent document . 1 . Upper extremity edema . 2 . Upper extremity pathology could interfere protocolspecified outcome assessment ( e.g. , cellulitis , lymphatic disorder prior surgery , preexist pain syndrome , previous mastectomy and/or axillary lymph node dissection , etc. ) . 3 . Contraindication antibody , know history anaphylactic severe systemic reaction . 4 . Known predisposition renal insufficiency renal failure , include diabetes mellitus , volume depletion , sepsis , paraproteinemia , subject receive know nephrotoxic drug . 5 . Known allergy hyaluronidase ingredient formulation Hylenex . 6 . Known allergy bee vespid venom . 7 . Known coagulopathy . 8 . Pregnancy breastfeed woman . 9 . Known clinically significant cardiovascular , gastrointestinal , hepatic , neurological , psychiatric , endocrine , cancer , HIV infection , diabetes mellitus , intercurrent illness influenza , major systemic disease would unduly risk subject 's safety interfere interpretation result . 10 . Participation study investigational drug device within 30 day enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>hyaluronidase</keyword>
	<keyword>subcutaneous drug delivery</keyword>
	<keyword>Volunteer Subjects</keyword>
</DOC>